Respiridone
Dear Medical Research Council,
Please could you give me information regarding the use of Respiridone between the years 1994 and 2002, including but not limited to:
1. Have there been any cases of fatalities from using Respiridone?
2. Have there been any injuries from using Respiridone?
3. What testing process did Respiridone go through before being approved as a prescription drug in the UK?
4. Has there been any action taken to withdraw the drug since its approval?
If you have any other information regarding the use of Respiridone, particularly around the year 2000 that would be gratefully received.
Yours faithfully,
Namaste Publishing
Thank you for your Freedom of Information request.
We will look into what information we have available and contact you again
shortly.
Tiffany Lay
Senior Information Officer
Medical Research Council
Dear Namaste Publishing,
Thank you for your freedom of information request.
We understand that 'Namaste Publishing' has been banned from 'What do they
know?' but that you will still be able to access this response. If you
have any further questions for the MRC on this issue please do contact us,
giving us your full name; as you may be aware the FOI Act requires the
requestor to provide their full name for the request to be valid.
As you may be aware, the Medical Research Council (MRC) supports the best
scientific research to improve human health. Its work ranges from
molecular level science to public health medicine and has led to
pioneering discoveries in our understanding of the human body and the
diseases which affect us all.
While the MRC has funded some research in this area we do not hold
information relating to the detailed questions (numbered 1-4). We suggest
that you approach the Medicines and Healthcare products Regulatory Agency
(http://www.mhra.gov.uk/index.htm) as the governmental agency with
responsibility for standards of safety, quality and performance, or the
National Institute for Health and Clinical Excellence
(http://www.nice.org.uk/) as the agency which develops national clinical
guidelines to secure consistent, high quality, evidence based care for
patients using the National Health Service.
In your request you go on to ask for 'any other information regarding the
use of Respiridone, particularly around the year 2000'
As noted above, the MRC has funded research involving Respiridone. One of
these projects, at the Institute of Psychiatry, King's College London,
resulted in: Donepezil for the Treatment of Agitation in Alzheimer's
Disease by Professor Robert Howard et al., published in the New England
Journal of Medicine 357;14 on October 4, 2007. Part way through this
research the use of Respiridone was withdrawn from the research. Details
can be found at: [1]http://www.mrc.ac.uk/Newspublications/Ne....
Funding for this study began in 2003 and ended in 2006.
Details of all research projects that are funded by the MRC can be found
in our research portfolio at:
[2]http://www.mrc.ac.uk/ResearchPortfolio/i....
I hope that you find the information we have been able to provide to you
to be useful and if you have any questions, or would like any further
information, please do let me know. However, if you are not satisfied that
this response has been handled appropriately, you may appeal using the
MRC's complaints procedure. Details are on the MRC website at:
www.mrc.ac.uk/index/about/about-contact/....
You may contact the MRC Complaints Officer by email at
[email address] or write to The Complaints Officer,
Medical Research Council, 14th Floor, One Kemble Street, London WC2B 4AN.
If, following the Complaints Officer's reply, you remain dissatisfied, you
may contact the Information Commissioner. Details of how to take your
complaint further are at www.informationcommissioner.gov.uk.
Tiffany
Tiffany Lay
Senior Information Officer
Medical Research Council
[3]www.mrc.ac.uk
We work to defend the right to FOI for everyone
Help us protect your right to hold public authorities to account. Donate and support our work.
Donate Now